Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8553 | 0.81 | ENPP2 (0.63) | ENPP2KDM4EALDH1A1MGLLLPL | |
| SCHEMBL138904 | 0.81 | ENPP2 (0.58) | ENPP2KDM4EALDH1A1MGLLCA1 | |
| SCHEMBL2557753 | 0.80 | ENPP2 (0.53) | ENPP2KDM4EALDH1A1MGLLLPL | |
| SCHEMBL4508412 | 0.79 | ENPP2 (0.56) | ENPP2KDM4EALDH1A1MGLL | |
| SCHEMBL28352473 | 0.79 | ENPP2 (0.56) | ENPP2KDM4EALDH1A1MGLLCA1 | |
| SCHEMBL17315528 | 0.79 | ENPP2 (0.51) | ENPP2KDM4EALDH1A1 | |
| SCHEMBL9502972 | 0.79 | AGXT (0.60) | ALDH1A1AGXTCA1CA2 | |
| SCHEMBL2549318 | 0.78 | ENPP2 (0.65) | ENPP2KDM4EALDH1A1MGLLCA1 | |
| SCHEMBL2554457 | 0.78 | ENPP2 (0.55) | ENPP2KDM4EALDH1A1MGLLCA1 | |
| SCHEMBL7992 | 0.78 | ENPP2 (0.59) | ENPP2KDM4EALDH1A1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081273-A1 | Serotonin Receptor-Targeting Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| EP-1730118-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081273-A1 | Serotonin Receptor-Targeting Compounds and Methods | HTR1A, HTR2C, HTR7 | ENPP2 643/4885KDM4E 2965/4885ALDH1A1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.